{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:38:43Z","timestamp":1790721523485,"version":"4.1.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002336","name":"Daiichi Sankyo Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ophthalmologyscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Science"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.xops.2026.101084","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T16:49:45Z","timestamp":1769014185000},"page":"101084","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Assessing the Safety and Efficacy of Agonistic Monoclonal Antibody against Robo4 versus Ranibizumab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Phase I, Open-Label, Multicenter Study"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4951-3320","authenticated-orcid":false,"given":"Rubbia","family":"Afridi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Senaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7756-3918","authenticated-orcid":false,"given":"Jaclyn Joyce","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nam","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0464-401X","authenticated-orcid":false,"given":"Zoha Zahid","family":"Fazal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan Dong","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasir","family":"Sepah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xops.2026.101084_bib1","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.2147\/CIA.S143508","article-title":"Recent developments in age-related macular degeneration: a review","volume":"12","author":"Al-Zamil","year":"2017","journal-title":"Clin Interv Aging"},{"key":"10.1016\/j.xops.2026.101084_bib2","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40942-019-0178-7","article-title":"Primary outcomes of the VIDI study: phase 2, double-masked, randomized, active-controlled study of ASP8232 for diabetic macular edema","volume":"5","author":"Nguyen","year":"2019","journal-title":"Int J Retina Vitr"},{"key":"10.1016\/j.xops.2026.101084_bib3","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2026.101084_bib4","article-title":"Anti-vascular endothelial growth factor for neovascular age-related macular degeneration","volume":"3","author":"Solomon","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.xops.2026.101084_bib5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s13554-012-0003-4","article-title":"Aflibercept: a potent vascular endothelial growth factor antagonist for neovascular age-related macular degeneration and other retinal vascular diseases","volume":"2","author":"Sophie","year":"2012","journal-title":"Biol Ther"},{"key":"10.1016\/j.xops.2026.101084_bib6","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ophtha.2010.02.031","article-title":"Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema","volume":"117","author":"Elman","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2026.101084_bib7","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1016\/j.ophtha.2010.08.016","article-title":"Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study","volume":"117","author":"Nguyen","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2026.101084_bib8","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER study investigators. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration","volume":"127","author":"Dugel","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2026.101084_bib9","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s12041-009-0068-0","article-title":"Mediators of ocular angiogenesis","volume":"88","author":"Qazi","year":"2009","journal-title":"J Genet"},{"key":"10.1016\/j.xops.2026.101084_bib10","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/978-1-4614-8090-7_7","article-title":"Roundabout receptors","volume":"8","author":"Ypsilanti","year":"2014","journal-title":"Adv Neurobiol"},{"key":"10.1016\/j.xops.2026.101084_bib11","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/nm1742","article-title":"Robo4 stabilizes the vascular network by inhibiting pathologic angiogenesis and endothelial hyperpermeability","volume":"14","author":"Jones","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.xops.2026.101084_bib12","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1038\/ncb1976","article-title":"Slit2-Robo4 signalling promotes vascular stability by blocking Arf6 activity","volume":"11","author":"Jones","year":"2009","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.xops.2026.101084_bib13","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20190513","article-title":"Regulatory mechanisms of Robo4 and their effects on angiogenesis","volume":"39","author":"Dai","year":"2019","journal-title":"Biosci Rep"},{"key":"10.1016\/j.xops.2026.101084_bib14","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1161\/ATVBAHA.124.320714","article-title":"Novel angiogenesis role of GLP-1(32\u201336) to rescue diabetic ischemic lower limbs via GLP-1R\u2013Dependent glycolysis in mice","volume":"44","author":"Zhang","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.xops.2026.101084_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s42003-024-06317-z","article-title":"Endothelial ROBO4 suppresses PTGS2\/COX-2 expression and inflammatory diseases","volume":"7","author":"Tanaka","year":"2024","journal-title":"Commun Biol"},{"key":"10.1016\/j.xops.2026.101084_bib16","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1167\/tvst.9.9.7","article-title":"DS-7080a, a selective Anti-ROBO4 antibody, shows anti-angiogenic efficacy with distinctly different profiles from Anti-VEGF agents","volume":"9","author":"Isumi","year":"2020","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.xops.2026.101084_bib17","first-page":"1961","article-title":"Anti-angiogenic effects of DS-7080a an Anti-ROBO4 monoclonal antibody, in a monkey model of LASER-induced choroidal neovascularization","volume":"58","author":"Inoue","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2026.101084_bib19","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/683025","article-title":"Role of ROBO4 signalling in developmental and pathological angiogenesis","volume":"2014","author":"Yadav","year":"2014","journal-title":"Biomed Res Int"}],"container-title":["Ophthalmology Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914526000229?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914526000229?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T09:41:02Z","timestamp":1778924462000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666914526000229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2666914526000229"],"URL":"https:\/\/doi.org\/10.1016\/j.xops.2026.101084","relation":{},"ISSN":["2666-9145"],"issn-type":[{"value":"2666-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessing the Safety and Efficacy of Agonistic Monoclonal Antibody against Robo4 versus Ranibizumab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Phase I, Open-Label, Multicenter Study","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xops.2026.101084","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Academy of Ophthalmology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101084"}}